**Author details**

Sarah K. Woody1 and Liqin Zhao1,2\*

\*Address all correspondence to: lzhao@ku.edu

1 Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA

2 Neuroscience Graduate Program, University of Kansas, Lawrence, KS, USA

### **References**


[4] National Institute on Aging. Alzheimer's Disease. 2015; 1–8 https://www.nia.nih.gov/ alzheimers/publication/alzheimers-disease-fact-sheet.

APOE and CLU share a number of important physiological properties. For instance, they are among the few proteins associated with brain lipoproteins [143, 144]. They interact with a shared set of cell-surface receptors [108] and both APOE and CLU promote neurite outgrowth [145, 146]. Moreover, elimination of either protein in an AD mouse model results in increased accumulation of Aβ [147]. Furthermore, presence of the C allele of the CLU AD-risk SNP has been shown to exacerbate the APOE ε4-mediated decrease in brain activity during executive attention tasks in young healthy dementia-free adults [148]. In addition, the genetic variance that results in increased AD risk from both genes is also associated with compromised or reduced protein expression and/or binding capabilities. Our data indicate that APOE protein expression levels are significantly increased in 6-month-old female Clu-/- mice. However, mCLU expression levels are significantly reduced in 6-month-old female human APOE ε4 gene targeted-replacement mice when compared to APOE ε3 mice indicating that reduced CLU expression may contribute to APOE ε4-mediated AD risk. Collectively, these studies indicate that APOE and CLU could share common risk pathways that contribute to the development of LOAD. Delineation of such pathways will potentially provide valuable insights for an increased understanding of the etiology of LOAD and ultimately help to devise therapeutic

1 Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas,

[1] Alzheimer's A. 2015 Alzheimer's disease facts and figures. Alzheimer's & Dementia:

[2] Why Do All the Large Alzheimer's Drug Trials Fail? [press release]. http:// www.dana.org/News/Why\_Do\_All\_the\_Large\_Alzheimer\_s\_Drug\_Trials\_Fail\_/: The

[3] Pharma counts just 3 Alzheimer's drug wins in 13 years (101 losses!) [press release]. http://www.fiercebiotech.com/story/pharma-counts-just-3-alzheimers-drug-wins-13-

2 Neuroscience Graduate Program, University of Kansas, Lawrence, KS, USA

The Journal of the Alzheimer's Association. 2015;11(3):332–84.

years-101-losses/2012-09-14: FierceBiotech, September 14, 2012.

strategies to prevent or reduce the risk of developing the disease.

and Liqin Zhao1,2\*

\*Address all correspondence to: lzhao@ku.edu

Dana Foundation, July 8, 2013.

**Author details**

334 Update on Dementia

Sarah K. Woody1

Lawrence, KS, USA

**References**


[27] Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics. 2009;41(10):1094–9.

[16] Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology. 2013;9(2):

[17] Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's disease neuroimaging initiative (ADNI). NeuroImage.

[18] Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. The Journal of Biological Chemistry. 2003;278(49):

[19] Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer

[20] Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes.

[21] Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative I. Sex modifies the APOE-related risk of developing Alzheimer disease.

[22] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis

[23] Fleisher A, Grundman M, Jack CR, Jr., Petersen RC, Taylor C, Kim HT, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impair‐

[24] Payami H, Montee KR, Kaye JA, Bird TD, Yu CE, Wijsman EM, et al. Alzheimer's

[25] Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, et al. Gender differ‐ ence in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. American Journal of Human

[26] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated

disease, apolipoprotein E4, and gender. JAMA. 1994;271(17):1316–7.

with Alzheimer's disease. Nature Genetics. 2009;41(10):1088–93.

106–18.

336 Update on Dementia

48529–33.

2009;45(4):1107–16.

disease. Neurology. 2009;72(17):1487–94.

Annals of Neurology. 2014;75(4):563–73.

consortium. JAMA. 1997;278(16):1349–56.

ment. Archives of Neurology. 2005;62(6):953–7.

Neurology. 2005;64(1):102–7.

Genetics. 1996;58(4):803–11.


teins from wild-type and human apoE transgenic mice. Neurochemistry International. 2001;39(5–6):415–25.

[52] Loison F, Debure L, Nizard P, le Goff P, Michel D, le Drean Y. Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. The Biochemical Journal. 2006;395(1):223–31.

[39] Burkey BF, deSilva HV, Harmony JA. Intracellular processing of apolipoprotein J precursor to the mature heterodimer. The Journal of Lipid Research. 1991;32(6):1039–

[40] Stewart EM, Aquilina JA, Easterbrook-Smith SB, Murphy-Durland D, Jacobsen C, Moestrup S, et al. Effects of glycosylation on the structure and function of the extrac‐

[41] Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. The Journal of Biological Chemistry.

[42] Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdorfer M. Nonsecreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-kappaB signaling

[43] Reddy KB, Jin G, Karode MC, Harmony JA, Howe PH. Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial

[44] de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure

[45] Nizard P, Tetley S, Le Drean Y, Watrin T, Le Goff P, Wilson MR, et al. Stress-induced retrotranslocation of clusterin/APOJ into the cytosol. Traffic. 2007;8(5):554–65.

[46] Pasinetti GM, Johnson SA, Oda T, Rozovsky I, Finch CE. Clusterin (SGP-2): a multi‐ functional glycoprotein with regional expression in astrocytes and neurons of the adult

[47] Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, et al. Clusterin secreted by astrocytes enhances neuronal differentiation from human neural

[48] Zwain IH, Grima J, Cheng CY. Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines. Molecular and Cellular Neurosciences. 1994;5(3):229–37.

[49] Xie Z, Harris-White ME, Wals PA, Frautschy SA, Finch CE, Morgan TE. Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. Journal of Neurochemistry.

[50] Kumita JR, Poon S, Caddy GL, Hagan CL, Dumoulin M, Yerbury JJ, et al. The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. Journal of Molecular Biolo‐

[51] DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, et al. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipopro‐

rat brain. The Journal of Comparative Neurology. 1994;339(3):387–400.

precursor cells. Cell Death and Differentiation. 2011;18(5):907–13.

ellular chaperone clusterin. Biochemistry. 2007;46(5):1412–22.

48.

338 Update on Dementia

2003;278(13):11590–600.

2005;93(4):1038–46.

gy. 2007;369(1):157–67.

pathway. PloS One. 2013;8(9):e75303.

cells. Biochemistry. 1996;35(19):6157–63.

and tissue distribution. Biochemistry. 1990;29(22):5380–9.


population. American Journal of Alzheimer's Disease and Other Dementias. 2011;26(8): 627–30.

[75] Schurmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. Journal of Alzheimer's Disease : JAD. 2011;25(3):421–4.

[63] Xue J, Lv DD, Jiao S, Zhao W, Li X, Sun H, et al. pVHL mediates K63-linked ubiquiti‐

[64] Lemansky P, Brix K, Herzog V. Subcellular distribution, secretion, and posttransla‐ tional modifications of clusterin in thyrocytes. Experimental Cell Research. 1999;251(1):

[65] Ghosh P, Hale EA, Lakshman MR. Plasma sialic-acid index of apolipoprotein J (SIJ): a

[66] Nuutinen T, Suuronen T, Kyrylenko S, Huuskonen J, Salminen A. Induction of clusterin/APOJ expression by histone deacetylase inhibitors in neural cells. Neuro‐

[67] Masoodi TA, Al Shammari SA, Al-Muammar MN, Alhamdan AA, Talluri VR. Explo‐ ration of deleterious single nucleotide polymorphisms in late-onset Alzheimer disease

[68] Braskie MN, Jahanshad N, Stein JL, Barysheva M, McMahon KL, de Zubicaray GI, et al. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience.

[69] Chen LH, Kao PY, Fan YH, Ho DT, Chan CS, Yik PY, et al. Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese

[70] Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically character‐ ized and neuropathologically verified individuals. Human Molecular Genetics.

[71] Ferrari R, Moreno JH, Minhajuddin AT, O'Bryant SE, Reisch JS, Barber RC, et al. Implication of common and disease specific variants in CLU, CR1, and PICALM.

[72] Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with

[73] Lancaster TM, Baird A, Wolf C, Jackson MC, Johnston SJ, Donev R, et al. Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. European Neuropsychopharmacology: The Journal of the European College of

[74] Ma JF, Liu LH, Zhang Y, Wang Y, Deng YL, Huang Y, et al. Association study of clusterin polymorphism rs11136000 with late onset Alzheimer's disease in Chinese Han

APOE genotypes. Archives of Neurology. 2010;67(12):1473–84.

nation of nCLU. PloS One. 2012;7(4):e35848.

chemistry International. 2005;47(8):528–38.

susceptibility genes. Gene. 2013;512(2):429–37.

population. Neurobiology of Aging. 2012;33(1):210 e1–7.

Neurobiology of Aging. 2012;33(8):1846 e7–18.

Neuropsychopharmacology. 2011;21(12):880–4.

new alcohol intake marker. Alcohol. 2001;25(3):173–9.

147–55.

340 Update on Dementia

2011;31(18):6764–70.

2010;19(16):3295–301.


[95] Zhang S, Li X, Ma G, Jiang Y, Liao M, Feng R, et al. CLU rs9331888 Polymorphism contributes to Alzheimer's disease susceptibility in Caucasian but not East Asian populations. Molecular Neurobiology. 2015.

[85] Yu JT, Ma XY, Wang YL, Sun L, Tan L, Hu N, et al. Genetic variation in clusterin gene and Alzheimer's disease risk in Han Chinese. Neurobiology of Aging. 2013;34(7):1921

[86] Lin YL, Chen SY, Lai LC, Chen JH, Yang SY, Huang YL, et al. Genetic polymorphisms of clusterin gene are associated with a decreased risk of Alzheimer's disease. European

[87] Pedraza O, Allen M, Jennette K, Carrasquillo M, Crook J, Serie D, et al. Evaluation of memory endophenotypes for association with CLU, CR1, and PICALM variants in black and white subjects. Alzheimer's & Dementia: The Journal of the Alzheimer's

[88] Lancaster TM, Brindley LM, Tansey KE, Sims RC, Mantripragada K, Owen MJ, et al. Alzheimer's disease risk variant in CLU is associated with neural inefficiency in healthy individuals. Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

[89] Erk S, Meyer-Lindenberg A, Opitz von Boberfeld C, Esslinger C, Schnell K, Kirsch P, et al. Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. The Journal of Neuroscience: The Official Journal of the Society for Neuro‐

[90] Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impair‐

[91] Roussotte FF, Gutman BA, Madsen SK, Colby JB, Thompson PM, Alzheimer's Disease Neuroimaging I. Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience.

[92] Shuai P, Liu Y, Lu W, Liu Q, Li T, Gong B. Genetic associations of CLU rs9331888 polymorphism with Alzheimer's disease: a meta-analysis. Neuroscience Letters.

[93] Toral-Rios D, Franco-Bocanegra D, Rosas-Carrasco O, Mena-Barranco F, Carvajal-Garcia R, Meraz-Rios MA, et al. Evaluation of inflammation-related genes polymor‐ phisms in Mexican with Alzheimer's disease: a pilot study. Frontiers in Cellular

[94] Xing YY, Yu JT, Cui WZ, Zhong XL, Wu ZC, Zhang Q, et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. Journal of Alzheimer's

e17–23.

342 Update on Dementia

Journal of Epidemiology. 2012;27(1):73–75.

Association. 2014;10(2):205–13.

science. 2011;31(49):18180–4.

ment. NeuroImage. 2012;59(1):212–7.

2015;11(10):1144–52.

2014;34(19):6537–45.

Neuroscience. 2015;9:148.

Disease: JAD. 2012;29(3):515–9.

2015;591:160–5.


[118] May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron. 1990;5(6):831–9.

[106] Bailey RW, Dunker AK, Brown CJ, Garner EC, Griswold MD. Clusterin, a binding protein with a molten globule-like region. Biochemistry. 2001;40(39):

[107] Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate APOJ-dependent clearance of cellular debris into nonprofessional phagocytes.

[108] Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strick‐ land DK, et al. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. The Journal of Biological Chemistry. 1995;270(22):13070–

[109] Lakins JN, Poon S, Easterbrook-Smith SB, Carver JA, Tenniswood MP, Wilson MR. Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry.

[110] Law GL, Griswold MD. Activity and form of sulfated glycoprotein 2 (clusterin) from cultured Sertoli cells, testis, and epididymis of the rat. Biology of Reproduction.

[111] Leeb C, Eresheim C, Nimpf J. Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-signaling pathway. The Journal of Biological Chemistry. 2014;289(7):

[112] Poon S, Rybchyn MS, Easterbrook-Smith SB, Carver JA, Pankhurst GJ, Wilson MR. Mildly acidic pH activates the extracellular molecular chaperone clusterin. The Journal

[113] Wyatt A, Yerbury J, Poon S, Dabbs R, Wilson M. Chapter 6: The chaperone action of Clusterin and its putative role in quality control of extracellular protein folding.

[114] Debure L, Vayssiere JL, Rincheval V, Loison F, Le Drean Y, Michel D. Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration.

[115] Dia VP, Mejia EG. Lunasin promotes apoptosis in human colon cancer cells by mito‐ chondrial pathway activation and induction of nuclear clusterin expression. Cancer

[116] Kimura K, Asami K, Yamamoto M. Effect of heat shock treatment on the production of variant testosterone-repressed prostate message-2 (TRPM-2) mRNA in culture cells.

[117] Lidstrom AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in

Alzheimer's disease. Experimental Neurology. 1998;154(2):511–21.

Experimental Cell Research. 2001;271(1):130–41.

of Biological Chemistry. 2002;277(42):39532–40.

Advances in Cancer Reserch. 2009;104:89–114.

Journal of Cell Science. 2003;116(Pt 15):3109–21.

Cell Biochemistry and Function. 1997;15(4):251–7.

Letters. 2010;295(1):44–53.

11828–40.

344 Update on Dementia

5.

2002;41(1):282–91.

1994;50(3):669–79.

4161–72.


[141] Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza RP, Fryer JD, et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxiaischemia. Nature Medicine. 2001;7(3):338–43.

[130] Choi NH, Mazda T, Tomita M. A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Molecular Immunology.

[131] Choi NH, Nakano Y, Tobe T, Mazda T, Tomita M. Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. International

[132] Kirszbaum L, Bozas SE, Walker ID. SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Letters.

[133] Van Beek J, Chan P, Bernaudin M, Petit E, MacKenzie ET, Fontaine M. Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia.

[134] Jun HO, Kim DH, Lee SW, Lee HS, Seo JH, Kim JH, et al. Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/ GSK-3beta signaling pathway. Experimental and Molecular Medicine. 2011;43(1):

[135] Kim N, Han JY, Roh GS, Kim HJ, Kang SS, Cho GJ, et al. Nuclear clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. Alcohol‐

[136] Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosen‐ sitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clinical Cancer Research: An Official Journal of the American Association for

[137] Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG, Papassideri IS, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53 activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clinical Cancer Research: An Official Journal of the American Association for Cancer

[138] Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nature Cell Biology.

[139] Schreiber SS, Tocco G, Najm I, Baudry M. Seizure activity causes a rapid increase in sulfated glycoprotein-2 messenger RNA in the adult but not the neonatal rat brain.

[140] Wehrli P, Charnay Y, Vallet P, Zhu G, Harmony J, Aronow B, et al. Inhibi‐ tion of post-ischemic brain injury by clusterin overexpression. Nature Medi‐

ism, Clinical and Experimental Research. 2012;36(1):72–82.

Cancer Research. 2000;6(5):1655–63.

Neuroscience Letters. 1993;153(1):17–20.

Research. 2009;15(1):48–59.

2005;7(9):909–15.

cine. 2001;7(9):977–9.

1989;26(9):835–40.

346 Update on Dementia

1992;297(1–2):70–6.

2000;31(1):39–50.

53–61.

Immunology. 1990;2(5):413–7.

